two weeks on semaglutide and no weight loss It has been nearly since the #semaglutide patent expired, India's weight-loss drug market is already opening up to cheaper generics. For a country grappling with a rising #obesity burden—driven My thoughts after 12 months

Experiences shared by clients are personal and may not reflect typical outcomes

Oral tirzepatide is in development and early availability, offering a needle-free option

A phase 3 trial of a higher-dose CagriSema formulation at 2.4/7.2 mg is planned for initiation in the second half of 2026, and the REDEFINE 11 trial, exploring CagriSemas full weight-loss potential, is expected to report data in the first half of 2027

In addition, while the homogenous nature of the prescribed dietary intake deficit, physical activity goal and counseling frequency provided consistency, it may not fully reflect the need for approaches tailored to the health profiles of individuals or to different populations in clinical practice